Latest News
-
2 Multibagger Defence To Shield Your Money, Buy On April 24; Prabhudas Sets Target Prices, Stop Loss -
Rs 3.5/Share Dividend Declared: NBFC Declares 55.5% YoY Surge In PAT, Shares Up 87% In 1-Yr -
Rs 118/Share Dividend: Healthcare Stock Below Rs 400 Turned Ex-Dividend, Payout Soon; Buy For Rs 515 Target -
6,693% Returns: Below Rs 75, Pharma Penny Stock Ex-Dividend For Rs 40/Sh Payout After 9 Years; Do You Own? -
TCS Vs Infosys Vs Wipro Shares, ADRs, Upcoming Dividends: Which Mega IT Stocks To Buy After Q4 Results? -
SBI Card Launches 3 New Variants of Its Travel Credit Card ‘SBI Card MILES’ -
25% Dividend Record Date: Logistic Stock Nears 1-Year High And It Belongs To Mahindra; Motilal Neutral -
1:10 Split, 26 Dividends: Tata's 26-Year-Old Retail Stock In Focus, Q4, Dividend Ahead; Buy For Target Rs 4200 -
1:5 Split Soon: Rs 2,300 Defence Stock To Split Into Five Shares, Rs 400 Cr Fundraising Too; Hits 52-Week High -
Penny Stock Bags Back-To-Back Orders Worth Rs 500 Mn, 110 Mn; Shares Hit Upper Circuit
Piramal Healthcare buy Vodafone stake from Essar. What does it mean for its shareholders'?
Rajesh Ladha, CFO Piramal Healthcare, was quoted by the newspaper Economic Times as "We can generate better returns in the short to medium term this way than by keeping our money in banks or liquid funds." Piramal will not contribute towards the day-to-day administration of the company, it will also not get a board seat.
According to the deal, Vodafone - Essar has been valued at $11.6 billion, this is much lower than what Essar had got from Uk based Vodafone had valued the company at $16 billion, as Essar reduced its stake in the company at the start of the year.
After the deal Vodafone's stake in the Indian company came to 75.35%. Since this was above the regulatory requirement, which state that FDI investment cannot be more than 74% in Indian telecom companies.
This deal there will be some respite for the Vodafone as it will be able to meet the regulatory norm of the holding. Vodafone also made announcements to the effect that it will be coming out with its IPO some time next year.
The IPO will provide Piramal an option to exit while claiming some profit provided the valuations do not fall any further.
Some television reports claimed that Vodafone has also agreed that if there is no IPO in two years, then Piramal will get $900 million in cash. Though, Piramal Healthcare any such clause.
The transaction was completed with HSBC as the adviser.
VIEW: There are two important things that should be taken note off.
First, the deal looks a bit risky from the Piramal Healthcare shareholders' perspective. An investment in telecom sector by a pharmaceutical company doesn't inspire a lot of confidence. There is every possibility that on an industry level the telecom industry has reached its low but if the over all economy goes for a down swing, this investment of Piramal Healthcare will result in bitter loss.
Second, few months back, the CEO of Vodafone had said the company can consider an IPO to meet the regulatory obligation. But now that it has come out as a written statement, the company is serious. This is good news for equity investors as they will get a chance to buy all the major telecom companies in India.
GoodReturns.in
